BRÈVE

sur Mainz BioMed N.V.

Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®

Mainz Biomed N.V., a leader in molecular genetic diagnostic solutions for early cancer detection, has announced a distribution partnership with Praxisdienst, the largest online retailer of medical products in Germany. This partnership, commencing in February 2024, aims to strengthen the availability of ColoAlert®, an innovative at-home screening test for colorectal cancer.

ColoAlert® differentiates itself from traditional screening methods by detecting tumor DNA in stools, providing a more comprehensive screening option. This approach enhances detection rates, especially for tumors that do not bleed, facilitating crucial early diagnosis for colorectal cancer treatment. Praxisdienst, renowned for its innovation and leadership, will expand access to this advanced diagnostic solution in Germany through its extensive distribution network.

Darin Leigh, CCO of Mainz Biomed, expressed excitement about this partnership, highlighting its alignment with the company's strategic goals and its commitment to improving diagnostic solutions in the healthcare sector. This partnership is seen as a significant step towards enhancing care standards and access to early colorectal cancer screening in Germany.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Mainz BioMed N.V.